Scarica l'app Stockscreener
158.55
3.86%
-6.3081
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$164.86
Aprire:
$161.51
Volume 24 ore:
715.36K
Relative Volume:
0.29
Capitalizzazione di mercato:
$34.18B
Reddito:
$606.42M
Utile/perdita netta:
$-1.28B
Rapporto P/E:
-24.76
EPS:
-6.403
Flusso di cassa netto:
$-997.58M
1 W Prestazione:
+7.38%
1M Prestazione:
+8.32%
6M Prestazione:
+3.73%
1 anno Prestazione:
+115.82%
Intervallo 1D:
$157.52
$164.53
Intervallo di 1 settimana:
$142.59
$166.00
Portata 52W:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
158.59 | 35.54B | 606.42M | -1.28B | -997.58M | -6.403 |
VRTX
Vertex Pharmaceuticals Inc
|
439.02 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.79 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.71 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.06 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.03 | 34.24B | 5.36B | 287.73M | 924.18M | 2.5229 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2025-12-19 | Ripresa | Truist | Buy |
| 2025-12-04 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
Insmed, Inc. (NASDAQ:INSM) Receives Average Rating of "Buy" from Analysts - marketbeat.com
INSM (NASDAQ: INSM) insider lists proposed Common share sales in Form 144 - Stock Titan
Insmed (NASDAQ: INSM) details $606M revenue and 150% stock gain - Stock Titan
Barclays Raises Price Target for Insmed (INSM) to $237 | INSM St - GuruFocus
Options Bulls Could Be Right About This Pharma Stock - Finviz
Insmed (INSM) poised for 2026 upside with potential $1.3B Arikayce sales boost, Roth/MKM initiates buy - MSN
INSMED (INSM) CLO exercises options and sells 19,638 shares under 10b5-1 plan - Stock Titan
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Insmed (INSM) - theglobeandmail.com
Insmed Shares Surge as Arikayce Trial Results Boost Investor Confidence - StocksToTrade
Stifel Lifts PT on Insmed Incorporated (INSM) to $208 From $205 – Here’s Why - Yahoo Finance
Insmed (INSM) jumps as Morgan Stanley raises PT by 28% - MSN
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance
Insmed (INSM) Jumps as Morgan Stanley Raises PT by 28% - Insider Monkey
10 Stocks Leaving the Market in the Dust Today: Insmed, FMC, Alcoa, and More - Insider Monkey
[144] INSMED Inc SEC Filing - Stock Titan
Insmed (NASDAQ:INSM) Stock Price Up 6.3% Following Analyst Upgrade - marketbeat.com
Stifel reiterates Insmed stock rating on rival trial success By Investing.com - Investing.com Canada
Leerink reiterates Insmed stock rating on TPIP franchise potential By Investing.com - Investing.com South Africa
Insmed stock gains on UTHR trial read-through, Morgan Stanley upgrade - Investing.com Canada
Leerink reiterates Insmed stock rating on TPIP franchise potential - Investing.com
Jefferies reiterates Insmed stock rating on inhaled prostacyclin validation By Investing.com - Investing.com Canada
Morgan Stanley upgrades Insmed stock rating on Brinsupri launch data - Investing.com
Morgan Stanley upgrades Insmed stock rating on Brinsupri launch data By Investing.com - Investing.com Canada
Equities Analysts Issue Forecasts for Insmed Q2 Earnings - MarketBeat
SG Americas Securities LLC Buys 49,356 Shares of Insmed, Inc. $INSM - marketbeat.com
Positive Phase 3b study update sees Insmed stock drop 1.56% - Traders Union
Nordea Investment Management AB Makes New Investment in Insmed, Inc. $INSM - marketbeat.com
Vanguard disaggregates holdings; Insmed (NASDAQ: INSM) shows 0 shares - Stock Titan
Assenagon Asset Management S.A. Sells 22,419 Shares of Insmed, Inc. $INSM - MarketBeat
INSM Stock: HC Wainwright & Co. Raises Price Target to $245 | IN - GuruFocus
Insmed (NASDAQ:INSM) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Insmed stock price target on ARIKAYCE data - Investing.com
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
Insmed shares rise on positive results from ARIKAYCE Phase 3b study - MSN
Insmed jumps 6.6% as attention returns to upcoming ENCORE readout for ARIKAYCE - Quiver Quantitative
Insmed CEO reveals Japan patient population exceeds US market for lung disease - AOL.com
Insmed (NASDAQ:INSM) Price Target Raised to $206.00 at Mizuho - MarketBeat
INSM Stock: Mizuho Raises Price Target Amid Stable Outlook | INS - GuruFocus
Insmed (NASDAQ:INSM) Price Target Upgrades Drive Nasdaq Index Focus - Kalkine Media
Wells Fargo Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $177 - Moomoo
INSM: Leerink Partners Raises Price Target, Maintains Outperform Rating | INSM Stock News - GuruFocus
INSM: Wells Fargo Raises Price Target to $177, Reaffirms Overwei - GuruFocus
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), GE Healthcare Technologies Inc (GEHC) and Insmed (INSM) - The Globe and Mail
B of A Securities Maintains Buy Rating for INSM, Raises Price Ta - GuruFocus
Insmed Stock Hits Day Low of $135.73 Amid Price Pressure - Markets Mojo
Apogee Therapeutics, Insmed, Sunoco - TradingView
Insmed (NASDAQ:INSM) Price Target Raised to $215.00 at Leerink Partners - marketbeat.com
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $143.69 to $243 - Moomoo
INSM shares rise following Arikayce's successful outcome in label expansion trial - Bitget
Stifel Nicolaus Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price - MarketBeat
INSM: Stifel Raises Price Target, Continues Buy Rating | INSM St - GuruFocus
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insmed Inc Azioni (INSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Smith Michael Alexander | Chief Legal Officer |
Mar 30 '26 |
Option Exercise |
24.78 |
19,638 |
486,582 |
71,509 |
| Smith Michael Alexander | Chief Legal Officer |
Mar 30 '26 |
Sale |
150.98 |
19,638 |
2,964,945 |
51,871 |
1.05%
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):